ashwagandha extract Report issue

Botanical Experimental
AACT PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CC1=C(CO)C(=O)O[C@H]([C@@H](C)[C@H]2CC[C@H]3[C@@H]4C[C@H]5O[C@]56[C@@H](O)C=CC(=O)[C@]6(C)[C@H]4CC[C@]23C)C1
  • InChIKey: DBRXOUCRJQVYJQ-BZMBVROXSA-N
  • Mol. Mass: 470.61
  • ALogP: 3.35
  • ChEMBL Molecule:
    withaferin a  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

ashwagandha | ashwagandha extract | sensoril

Organizations (24)

Research & Development (24)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (1)


 

Stress, Psychological

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Aging (Early Phase 1)

Anxiety Disorders (Phase 2)

Autoimmune Diseases (Phase 1)

Bipolar Disorder (Phase 3)

Breast Neoplasms (Phase 2)

Chemotherapy-Related Cognitive Impairment (Phase 2)

Chronic Periodontitis (Phase 1/Phase 2)

Craving (Phase 3)

Healthy Volunteers (Early Phase 1)

Inflammation (Phase 1)

Neoplasms (Phase 1)

Obesity (Phase 3)

Osteosarcoma (Phase 1/Phase 2)

Ovarian Neoplasms (Phase 1/Phase 2)

Psychological Distress (Phase 3)

Schizophrenia (Phase 2/Phase 3)

Sexual Health (Phase 4)

Sleep (Phase 2)

Sleep Disorders, Intrinsic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial Organizations: 24

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue